At AAVACC Pte Ltd we are focused on developing novel veterinary vaccines using ACM technology developed by our parent company, ACM Biolabs Pte Ltd. Artificial Cell Membrane (“ACM”) technology allows us to stabilize and deliver functional, folded viral and bacterial cell-surface antigens to induce a strong immune reaction. The safety of the platform technology has been demonstrated and efficacy via both injected and oral dosages using has been proven. We are currently scaling up and bringing our first vaccines through regulatory approvals, however we are open to licensing or co-development of vaccines with animal health partners.

The company was incorporated in Singapore in 2017.



AAVACC Pte Ltd is majority owned by its parent company, ACM Biolabs Pte Ltd, the remaining equity of the company is held by strategic partners, such as San Pacific Investments Pte Ltd.